Major Ingredients

Depomed 2 Tablet: Each TabletContains Methylprednisolone USP 2mg.

Major Functionality

It is indicated for the treatment of 1. Endocrine Disorders: Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, non suppurative thyroiditis, hypercalcemia associated with cancer 2. RheumaticDisorders: Rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis, acute and subacute bursitis, synovitis of osteoarthritis, acute non-specific tenosynovitis, post-traumatic osteoarthritis, psoriatic arthritis, epicondylitis, acute gouty arthritis 3. Collagen Diseases: Systemic lupus erythematosus systemic dermatomyositis, acute rheumatic carditis 4. Dermatologic Diseases: Bullous dermatitis herpetiformis, severe erythema multiforme, severe seborrheic dermatitis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe psoriasis 5. Allergic States: Seasonal or perennial allergic rhinitis, drug hypersensitivity reactions, serum sickness, contact dermatitis, bronchial asthma, atopic dermatitis 6. Ophthalmic Diseases: Allergic corneal marginal ulcers, herpes zoster ophthalmicus, anterior segment inflammation, sympathetic ophthalmic, keratitis, optic neuritis, allergic conjunctivitis chorioretinitis, iritis and iridocyclitis 7. Respiratory Diseases: Symptomatic sarcoidosis, berylliosis, loeffler's syndrome not manageable by other means, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti tuberculous chemotherapy, aspiration pneumonitis 8. Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), congenital (erythroid) hypo plastic anemia 9. Neoplastic Diseases: For palliative management of: Leukemia’s and lymphomas in adults, acute leukemia of childhood 10. Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases: U

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.